根治性膀胱切除术后膀胱癌队列中FGFR3突变状态与FGFR3表达及其对抗FGFR3治疗的提示
该研究在1000例未接受化疗的根治性膀胱切除标本中分析FGFR3突变、FGFR3及p53蛋白表达及其预后价值。结果显示FGFR3突变见于11%肿瘤,FGFR3过表达见于28%,p53过表达见于69%。FGFR3突变与较低pT分期、较低肿瘤分级、无原位癌、pN0、低水平p53及较长疾病特异性生存(DSS)显著相关;FGFR3过表达仅与较低pT分期和肿瘤分级相关,且在FGFR3野生型肿瘤中与DSS无关。结论提示FGFR3突变具有驱动作用,与FGFR3过表达功能不同,FGFR3突变患者更可能从抗FGFR3治疗中获益。
要点
- FGFR3突变见于11%根治性膀胱切除标本,与较好病理特征和较长DSS相关。
- FGFR3过表达见于28%肿瘤,仅与较低pT分期和分级相关,在野生型中与DSS无关。
- FGFR3突变与过表达功能不同,突变患者更可能从抗FGFR3治疗中获益。
核心结论
- FGFR3突变可识别根治性膀胱切除术后预后较好的膀胱癌患者。
- FGFR3突变与FGFR3过表达功能不同,突变患者更可能从抗FGFR3治疗中获益。
研究设计与样本
- 研究纳入1000例未接受化疗的根治性膀胱切除标本,分析FGFR3突变、FGFR3及p53蛋白表达并评估预后价值。
主要发现
- FGFR3突变见于11%肿瘤,FGFR3过表达见于28%,p53过表达见于69%。
- FGFR3突变肿瘤中73%存在FGFR3过表达,而FGFR3野生型肿瘤中为22%。
- FGFR3突变显著与较低pT分期、较低肿瘤分级、无原位癌、pN0、低水平p53及较长DSS相关。
- FGFR3过表达仅与较低pT分期和肿瘤分级相关,在FGFR3野生型肿瘤中与DSS无关。
临床怎么用
- 根治性膀胱切除标本可检测FGFR3突变以识别预后较好且可能从抗FGFR3治疗获益的患者。
局限性
- 原文指出需进一步研究验证FGFR3突变患者更可能从抗FGFR3治疗获益的假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-invasive BC. We analyzed FGFR3 mutations, FGFR3, and p53 protein expression and assessed their prognostic value in a cohort of 1000 chemotherapy-naive radical cystectomy specimens. FGFR3 mutations were found in 11%, FGFR3 overexpression was found in 28%, and p53 overexpression was found in 69% of tumors. Among FGFR3 mutant tumors, 73% had FGFR3 overexpression versus 22% among FGFR3 wild-type tumors. FGFR3 mutations were significantly associated with lower pT stage, tumor grade, absence of carcinoma in situ, pN0, low-level p53, and longer disease-specific survival (DSS). FGFR3 overexpression was associated only with lower pT stage and tumor grade. Moreover, FGFR3 overexpression was not associated with DSS in patients with FGFR3 wild-type tumors. In conclusion, FGFR3 mutations identified patients with favorable BC at cystectomy. Our results suggest that FGFR3 mutations have a driver role and are functionally distinct from FGFR3 overexpression. Hence, patients with FGFR3 mutations would be more likely to benefit from anti-FGFR3 therapy. Ideally, further research is needed to test this hypothesis. PATIENT SUMMARY: Oncogenic fibroblast growth factor receptor 3 (FGFR3) mutations are very common in bladder cancer. In this report, we found that these FGFR3 mutations were associated with favorable features and prognosis of bladder cancer compared with patients with FGFR3 overexpressed tumors only. As a consequence, patients with FGFR3 mutant tumors would be more likely to benefit from anti-FGFR3 therapy than patients with FGFR3 protein overexpression only.
引用
- van Rhijn BWG, Mertens LS, Mayr R, et al. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†. Eur Urol. 2020. PMID: 32682615. doi:10.1016/j.eururo.2020.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。